Thiazolidinedione inhibits the production of monocyte chemoattractant protein‐1 in cytokine‐treated human vascular endothelial cells

FEBS Letters

Ishida, Toshihiko¹  Sayo, Yoshitaka¹  Hosokawa, Hitoshi¹  Imachi, Hitomi¹  Momoi, Atsuko¹  Murao, Koji¹  Sato, Makoto¹  Takahara, Jiro¹ 

[1] First Department of Internal Medicine, Kagawa Medical University, 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan

关键词: Monocyte chemoattractant protein-1;    Thiazolidinedione;    Interleukin-1β;    Tumor necrosis factor-α;    Human vascular endothelial cell;    PCR;    polymerase chain reaction;    MCP-1;    monocyte chemoattractant protein-1;    TZD;    thiazolidinediones;    PPAR-γ;    peroxisome proliferator-activated receptor-γ;    IL-1β;    interleukin-1β;    TNF-α;    tumor necrosis factor-α;    ELISA;    enzyme-linked immunosorbent assay;   

DOI  :  10.1016/S0014-5793(99)00765-6

学科分类：生物化学/生物物理

来源: John Wiley & Sons Ltd.

【 摘 要 】

The chemokine monocyte chemoattractant protein-1 is a potent chemoattractant for monocytes. Monocyte chemoattractant protein-1 is produced by vascular endothelial cells during inflammatory diseases such as atherosclerosis. In this study, we examined the effects of a thiazolidinedione on monocyte chemoattractant protein-1 expression in human vascular endothelial cells. In human vascular endothelial cells, interleukin-1β and tumor necrosis factor-α induced endogenous monocyte chemoattractant protein-1 protein secretion, mRNA expression and promoter activity. The thiazolidinedione inhibited these effects. In summary, our results indicated that the suppression of the expression of monocyte chemoattractant protein-1 can be accomplished by thiazolidinedione treatment, raising the possibility that thiazolidinedione may be of therapeutic value in the treatment of diseases such as atherosclerosis.

【 授权许可】

Unknown